JPWO2020163365A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020163365A5
JPWO2020163365A5 JP2021545400A JP2021545400A JPWO2020163365A5 JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5 JP 2021545400 A JP2021545400 A JP 2021545400A JP 2021545400 A JP2021545400 A JP 2021545400A JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5
Authority
JP
Japan
Prior art keywords
zc3h12a
socs1
optionally
immune effector
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021545400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519595A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016623 external-priority patent/WO2020163365A2/en
Publication of JP2022519595A publication Critical patent/JP2022519595A/ja
Publication of JPWO2020163365A5 publication Critical patent/JPWO2020163365A5/ja
Pending legal-status Critical Current

Links

JP2021545400A 2019-02-04 2020-02-04 免疫療法の改善のための遺伝子標的の組み合わせ Pending JP2022519595A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962800999P 2019-02-04 2019-02-04
US62/800,999 2019-02-04
US201962818677P 2019-03-14 2019-03-14
US62/818,677 2019-03-14
PCT/US2020/016623 WO2020163365A2 (en) 2019-02-04 2020-02-04 Combination gene targets for improved immunotherapy

Publications (2)

Publication Number Publication Date
JP2022519595A JP2022519595A (ja) 2022-03-24
JPWO2020163365A5 true JPWO2020163365A5 (zh) 2023-02-10

Family

ID=71947815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545400A Pending JP2022519595A (ja) 2019-02-04 2020-02-04 免疫療法の改善のための遺伝子標的の組み合わせ

Country Status (12)

Country Link
US (1) US20200347386A1 (zh)
EP (1) EP3920942A4 (zh)
JP (1) JP2022519595A (zh)
KR (1) KR20210138587A (zh)
CN (1) CN113396216A (zh)
AU (1) AU2020217715A1 (zh)
BR (1) BR112021015170A2 (zh)
CA (1) CA3128823A1 (zh)
IL (1) IL285307A (zh)
MX (1) MX2021009357A (zh)
SG (1) SG11202108452WA (zh)
WO (1) WO2020163365A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
KR20230056766A (ko) * 2020-08-28 2023-04-27 제넨테크, 인크. 숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
US20240060091A1 (en) * 2020-12-17 2024-02-22 University of Florida Research Foundation, Incorporation Method for programmable control of rna transcript levels with autoregulated crispr-cas13d
US20220288122A1 (en) * 2021-03-09 2022-09-15 Crispr Therapeutics Ag Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
WO2023015213A1 (en) * 2021-08-03 2023-02-09 Spotlight Therapeutics Ptpn2 specific guide rnas and uses thereof
WO2023082640A1 (zh) * 2021-11-10 2023-05-19 清华大学 增强免疫细胞持久性的方法
WO2023096928A1 (en) * 2021-11-23 2023-06-01 Kumquat Biosciences Inc. Hetero-atom containing compounds and uses thereof
WO2023131053A1 (zh) * 2022-01-05 2023-07-13 苏州系统医学研究所 一种t细胞受体及其制备方法和用途
WO2023143515A1 (zh) * 2022-01-29 2023-08-03 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348139B1 (en) * 2001-04-13 2008-03-25 The Johns Hopkins University School Of Medicine SOCS-1 gene methylation in cancer
US20130331294A1 (en) * 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2010098429A1 (ja) * 2009-02-27 2010-09-02 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
CN111218447A (zh) * 2013-11-07 2020-06-02 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
WO2018148378A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
AU2019236205A1 (en) * 2018-03-15 2020-10-08 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy

Similar Documents

Publication Publication Date Title
JP2021164463A (ja) エピゲノム編集のための組成物および方法
Bernstein et al. TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts
JP2021534810A (ja) Ｒｎａを編集する方法および組成物
Lawrie Micro RNA s and lymphomagenesis: a functional review
Soldevilla et al. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
JP2022526455A (ja) Ｒｎａを編集する方法および組成物
JPWO2019178422A5 (zh)
CN116322716A (zh) Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
JP2017513520A (ja) メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
US20220169984A1 (en) Improved process for dna integration using rna-guided endonucleases
US20220145333A1 (en) Improved process for integration of dna constructs using rna-guided endonucleases
JP2021502077A5 (zh)
JP2022513586A (ja) 抗ｌｉｖ１免疫細胞癌療法
JPWO2020163365A5 (zh)
JP2022519070A (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2022509017A (ja) 抗ｐｔｋ７免疫細胞癌療法
CN108495640B (zh) 短发夹rna(shrna734)及其用于阳性选择和消除遗传修饰的细胞的用途
WO2022261115A1 (en) Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022012531A1 (zh) 一种经修饰的免疫细胞的制备方法
JPWO2019178420A5 (zh)
JPWO2019178421A5 (zh)
JPWO2021136263A5 (zh)
WO2022015956A1 (en) Improved process for dna integration using rna-guided endonucleases
JPWO2020176740A5 (zh)
CN112823209A (zh) 使用编码高度紧凑的多输入逻辑门的核酸载体治疗疾病的方法